My Stocks Explore Events Please signup to use this feature
Please signup to use this feature
Please signup to use this feature
Please signup to use this feature
Live today
{{event.ticker}} @{{event.event_utc_datetime | date:'h:mm a'}}
{{market.market_short_name}} {{market.last_price | number : 2}}

Want to join the conversation?

$PHM {{ '2015-10-22T12:01:10+0000' | timeago}} • Announcement

$PHM's 3Q15 net new orders were 4,092 homes, which was up 8% from the prior year. On a dollar basis, 3Q15 signup value was $1.5Bil, a growth of 17% from 3Q14. $PHM operated from 611 active communities in 3Q15, which was up 2% from last year.

User Melwyn Jones {{ '2016-10-28T17:16:30+0000' | timeago}}

$CVX posts first profit in a year. Right time to get some shares? My question is, will it sustain this turnaround?

User Josh Allan {{ '2016-10-27T15:39:01+0000' | timeago}}

Jeff Bezos, my inspiration next to Steve Jobs is going to review the Everything Store $AMZN's financial results today after hours. As an investor/user, I like Amazon Prime and it's success over several parts of the world. What's your take on Amazon?

User RC xNair {{ '2016-10-27T13:31:32+0000' | timeago}}

Of all the Wall St firms out there, Goldman Sachs $GS is the most revered for the way they're run - hiring the best, highly competitive, a closely-knit peer group and making tons of profits for the shareholders. An interesting interview of its CEO Llyod Blankfein by Carlyle groups chief David Rubenstein

User Ramesh Raju {{ '2016-10-27T10:38:07+0000' | timeago}}

Deutsche Bank posts Q3 net profit of 278 million euros.

User Vishnu Beri {{ '2016-10-27T01:52:28+0000' | timeago}}

Great results from $TSLA, however the question remains if Tesla can continue to scale up to produce the cars in the quantity it promises. Model 3 numbers need to be in multiples of what they are producing right now. Wish them the best, will keep an eye as I am still not convinced that they can scale easily.

$ABBV {{ '2016-10-28T18:24:35+0000' | timeago}} • Webcast

For 4Q16, $ABBV forecasts sales growth in excess of 20% for HUMIRA, which will contribute to the company's full year 2016 forecast of above 20%. The company continues to forecast HUMIRA international operational sales growth in the mid single digits for the full year.

$ABBV {{ '2016-10-28T18:21:43+0000' | timeago}} • Webcast

In 3Q16, $ABBV said HUMIRA's global sales were more than $4Bil, up 12.1% operationally. Globally, the company continues to see strong volume growth across all therapeutic segments. HUMIRA sales in the US grew 16.7% versus the prior year. The growth rate was negatively impacted by 4 points, due to higher customer ordering patterns in the prior year.

$ALXN {{ '2016-10-28T18:18:50+0000' | timeago}} • Webcast

$ALXN has almost 40 patients with ALXN1210, so the company has that deal of empiric data, which helps inform both the dose and interval. As it relates to the 8-week dosing interval, the company anticipates in the trials that the infusion time would be about two hours.

$ESS {{ '2016-10-28T18:16:50+0000' | timeago}} • Webcast

$ESS expects about a 20% drop in apartment supply in San Francisco and nearly 30% in San Jose in 2017 and fewer deliveries in each quarter in 2017. The company expects supply pressures to moderate in Northern California, especially in 2H17 assuming the job growth remains on track.

$PSX {{ '2016-10-28T18:11:44+0000' | timeago}} • Webcast

$PSX said its petrochemical partner CPChem is advancing US Gulf Coast Petrochemicals Project, which is about 85% complete. The polyethylene units are expected to be completed by mid-2017, and ethylene cracker units are expected to be completed in the second half of 2017.